{"transactions":[{"id":758379,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T21:39:56.000Z","date":"2026-05-27","kind":"gift","planned":false,"acquired":false,"shares":724637,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift for no consideration to a 501(c)(3) charitable foundation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Malcom and Emily Fairbairn 2010 CRUT (the \"CRUT\"). The Reporting Person is a trustee of the CRUT."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001682638-26-000006","document":"form4-05292026_090552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000168263826000006/form4-05292026_090552.xml","form_type":"4"}},{"id":781933,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-12T20:30:27.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":154500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":154500,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":154500},"source":{"system":"sec-edgar","filing":"0001830914-26-000004","document":"form4-05122026_040514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000183091426000004/form4-05122026_040514.xml","form_type":"4"}},{"id":782666,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47995,"kind":"person","name":"Greenwood Luba","position":1,"cik":"0001853815","reported_name":"Greenwood Luba","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T20:30:25.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":22000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001853815-26-000002","document":"form4-05122026_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853815/000185381526000002/form4-05122026_040512.xml","form_type":"4"}},{"id":781932,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47898,"kind":"person","name":"Lamb Lawrence","position":1,"cik":"0001830059","reported_name":"Lamb Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CSO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-12T20:30:23.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":54000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001830059-26-000004","document":"form4-05122026_040519.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000183005926000004/form4-05122026_040519.xml","form_type":"4"}},{"id":781947,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T20:30:22.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":22000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001682638-26-000004","document":"form4-05122026_040510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000168263826000004/form4-05122026_040510.xml","form_type":"4"}},{"id":783363,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-12T20:30:21.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":56250,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001874384-26-000004","document":"form4-05122026_040517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000187438426000004/form4-05122026_040517.xml","form_type":"4"}},{"id":782735,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-12T20:30:19.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":60000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001898521-26-000004","document":"form4-05122026_040516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000189852126000004/form4-05122026_040516.xml","form_type":"4"}},{"id":781931,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47897,"kind":"person","name":"Epperly Corinne","position":1,"cik":"0001839156","reported_name":"Epperly Corinne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T20:30:19.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":22000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001839156-26-000002","document":"form4-05122026_040508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000183915626000002/form4-05122026_040508.xml","form_type":"4"}},{"id":782242,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T20:30:13.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":22000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001434099-26-000002","document":"form4-05122026_040506.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000143409926000002/form4-05122026_040506.xml","form_type":"4"}},{"id":781930,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47896,"kind":"person","name":"Graff Jeremy R.","position":1,"cik":"0001975028","reported_name":"Graff Jeremy R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T20:30:08.000Z","date":"2026-05-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":22000,"derivative":{"exercise_price":1.58,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001975028-26-000002","document":"form4-05122026_040505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000197502826000002/form4-05122026_040505.xml","form_type":"4"}},{"id":915678,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47898,"kind":"person","name":"Lamb Lawrence","position":1,"cik":"0001830059","reported_name":"Lamb Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CSO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-06T21:30:27.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":72000,"derivative":{"exercise_price":1.96,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001830059-26-000002","document":"form4-02062026_040221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000183005926000002/form4-02062026_040221.xml","form_type":"4"}},{"id":916736,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-06T21:30:26.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":75000,"derivative":{"exercise_price":1.96,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001874384-26-000002","document":"form4-02062026_040219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000187438426000002/form4-02062026_040219.xml","form_type":"4"}},{"id":916152,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-06T21:30:23.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":80000,"derivative":{"exercise_price":1.96,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001898521-26-000002","document":"form4-02062026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000189852126000002/form4-02062026_040217.xml","form_type":"4"}},{"id":915677,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-06T21:30:22.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":206000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":206000,"derivative":{"exercise_price":1.96,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001830914-26-000002","document":"form4-02062026_040216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000183091426000002/form4-02062026_040216.xml","form_type":"4"}},{"id":959807,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:20:14.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":7247,"price":1.38,"value":10000.86,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":9085,"source":{"system":"sec-edgar","filing":"0001898521-25-000003","document":"form4-12232025_061210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000189852125000003/form4-12232025_061210.xml","form_type":"4"}},{"id":960289,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-12-23T23:20:12.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":7247,"price":1.38,"value":10000.86,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":9482,"source":{"system":"sec-edgar","filing":"0001874384-25-000003","document":"form4-12232025_061208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000187438425000003/form4-12232025_061208.xml","form_type":"4"}},{"id":959303,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-12-23T23:20:11.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":36232,"price":1.38,"value":50000.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":121168,"source":{"system":"sec-edgar","filing":"0001830914-25-000003","document":"form4-12232025_061207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000183091425000003/form4-12232025_061207.xml","form_type":"4"}},{"id":959519,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:20:06.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":72464,"price":1.38,"value":100000.32,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":95181,"source":{"system":"sec-edgar","filing":"0001434099-25-000004","document":"form4-12232025_061203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000143409925000004/form4-12232025_061203.xml","form_type":"4"}},{"id":959308,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:20:05.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":724637,"price":1.38,"value":999999.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Malcom and Emily Fairbairn 2010 CRUT (the \"CRUT\"). The Reporting Person is a trustee of the CRUT."}],"balance_after":724637,"source":{"system":"sec-edgar","filing":"0001682638-25-000004","document":"form4-12232025_061201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000168263825000004/form4-12232025_061201.xml","form_type":"4"}},{"id":959595,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T18:20:08.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":36232,"price":1.38,"value":50000.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":49514,"source":{"system":"sec-edgar","filing":"0001643070-25-000005","document":"form4-12232025_061205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000164307025000005/form4-12232025_061205.xml","form_type":"4"}},{"id":1152312,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47995,"kind":"person","name":"Greenwood Luba","position":1,"cik":"0001853815","reported_name":"Greenwood Luba","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T20:15:24.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":63150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":63150,"derivative":{"exercise_price":0.17,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":63150},"source":{"system":"sec-edgar","filing":"0001415889-25-012654","document":"form4-05122025_040520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853815/000141588925012654/form4-05122025_040520.xml","form_type":"4"}},{"id":1151912,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47896,"kind":"person","name":"Graff Jeremy R.","position":1,"cik":"0001975028","reported_name":"Graff Jeremy R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T20:15:22.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":63150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":63150,"derivative":{"exercise_price":0.17,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":63150},"source":{"system":"sec-edgar","filing":"0001415889-25-012653","document":"form4-05122025_040518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012653/form4-05122025_040518.xml","form_type":"4"}},{"id":1151937,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T20:15:20.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":63150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":63150,"derivative":{"exercise_price":0.17,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":63150},"source":{"system":"sec-edgar","filing":"0001415889-25-012652","document":"form4-05122025_040514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000141588925012652/form4-05122025_040514.xml","form_type":"4"}},{"id":1151913,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47897,"kind":"person","name":"Epperly Corinne","position":1,"cik":"0001839156","reported_name":"Epperly Corinne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T20:15:17.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":63150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":63150,"derivative":{"exercise_price":0.17,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":63150},"source":{"system":"sec-edgar","filing":"0001415889-25-012651","document":"form4-05122025_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012651/form4-05122025_040512.xml","form_type":"4"}},{"id":1152137,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T20:15:13.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":63150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":63150,"derivative":{"exercise_price":0.17,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":63150},"source":{"system":"sec-edgar","filing":"0001415889-25-012650","document":"form4-05122025_040509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012650/form4-05122025_040509.xml","form_type":"4"}},{"id":1152179,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T16:15:11.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":63150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":63150,"derivative":{"exercise_price":0.17,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":63150},"source":{"system":"sec-edgar","filing":"0001415889-25-012649","document":"form4-05122025_040507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012649/form4-05122025_040507.xml","form_type":"4"}},{"id":1155875,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47898,"kind":"person","name":"Lamb Lawrence","position":1,"cik":"0001830059","reported_name":"Lamb Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CSO"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:21.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":1639,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":1639,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":1639},"source":{"system":"sec-edgar","filing":"0001415889-25-012293","document":"form4-05072025_080516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012293/form4-05072025_080516.xml","form_type":"4"}},{"id":1155874,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47898,"kind":"person","name":"Lamb Lawrence","position":1,"cik":"0001830059","reported_name":"Lamb Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CSO"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:21.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1639,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 1,639 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 1,639 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":1639},"source":{"system":"sec-edgar","filing":"0001415889-25-012293","document":"form4-05072025_080516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012293/form4-05072025_080516.xml","form_type":"4"}},{"id":1155873,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47896,"kind":"person","name":"Graff Jeremy R.","position":1,"cik":"0001975028","reported_name":"Graff Jeremy R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:17.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":2049,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":2049,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":2049},"source":{"system":"sec-edgar","filing":"0001415889-25-012292","document":"form4-05072025_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012292/form4-05072025_080513.xml","form_type":"4"}},{"id":1155872,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47896,"kind":"person","name":"Graff Jeremy R.","position":1,"cik":"0001975028","reported_name":"Graff Jeremy R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:17.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2049,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 2,049 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":2049},"source":{"system":"sec-edgar","filing":"0001415889-25-012292","document":"form4-05072025_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012292/form4-05072025_080513.xml","form_type":"4"}},{"id":1155871,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47897,"kind":"person","name":"Epperly Corinne","position":1,"cik":"0001839156","reported_name":"Epperly Corinne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:15.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":81967,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012291","document":"form4-05072025_080511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012291/form4-05072025_080511.xml","form_type":"4"}},{"id":1155870,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47897,"kind":"person","name":"Epperly Corinne","position":1,"cik":"0001839156","reported_name":"Epperly Corinne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:15.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012291","document":"form4-05072025_080511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012291/form4-05072025_080511.xml","form_type":"4"}},{"id":1155869,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-05-08T00:45:13.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":81967,"price":0.1843,"value":15106.5181,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the \"Exchange Agreement\"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock,  with a per share exercise price of $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Pre-Funded Warrants are subject to certain exercise limitations."}],"balance_after":81967,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012290","document":"form4-05072025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012290/form4-05072025_080509.xml","form_type":"4"}},{"id":1155868,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:13.000Z","date":"2025-05-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the \"Exchange Agreement\"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock,  with a per share exercise price of $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012290","document":"form4-05072025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012290/form4-05072025_080509.xml","form_type":"4"}},{"id":1155867,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:13.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":81967,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012290","document":"form4-05072025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012290/form4-05072025_080509.xml","form_type":"4"}},{"id":1155866,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:13.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to\npurchase 81,967 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012290","document":"form4-05072025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925012290/form4-05072025_080509.xml","form_type":"4"}},{"id":1156307,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:11.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":12295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":12295,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-25-012289","document":"form4-05072025_080507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925012289/form4-05072025_080507.xml","form_type":"4"}},{"id":1156306,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:11.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-25-012289","document":"form4-05072025_080507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925012289/form4-05072025_080507.xml","form_type":"4"}},{"id":1156305,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:11.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":12295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-25-012289","document":"form4-05072025_080507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925012289/form4-05072025_080507.xml","form_type":"4"}},{"id":1156304,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:11.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":12295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":12295,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-25-012289","document":"form4-05072025_080507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925012289/form4-05072025_080507.xml","form_type":"4"}},{"id":1156303,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:11.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-25-012289","document":"form4-05072025_080507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925012289/form4-05072025_080507.xml","form_type":"4"}},{"id":1156302,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-08T00:45:11.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":12295,"price":0.1844,"value":2267.198,"ownership":{"direct":true},"balance_after":55169,"source":{"system":"sec-edgar","filing":"0001415889-25-012289","document":"form4-05072025_080507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925012289/form4-05072025_080507.xml","form_type":"4"}},{"id":1156707,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:09.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":20492,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":20492,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":20492},"source":{"system":"sec-edgar","filing":"0001415889-25-012288","document":"form4-05072025_080505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925012288/form4-05072025_080505.xml","form_type":"4"}},{"id":1156706,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:09.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20492,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":20492},"source":{"system":"sec-edgar","filing":"0001415889-25-012288","document":"form4-05072025_080505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925012288/form4-05072025_080505.xml","form_type":"4"}},{"id":1156705,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:09.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-012288","document":"form4-05072025_080505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925012288/form4-05072025_080505.xml","form_type":"4"}},{"id":1156704,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:09.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":15000,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-012288","document":"form4-05072025_080505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925012288/form4-05072025_080505.xml","form_type":"4"}},{"id":1156703,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:09.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":5492,"derivative":{"exercise_price":0.45,"expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-012288","document":"form4-05072025_080505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925012288/form4-05072025_080505.xml","form_type":"4"}},{"id":1156702,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-05-08T00:45:09.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.1844,"value":2766.0,"ownership":{"direct":true},"balance_after":67071,"source":{"system":"sec-edgar","filing":"0001415889-25-012288","document":"form4-05072025_080505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925012288/form4-05072025_080505.xml","form_type":"4"}},{"id":1156102,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":81967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156101,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 and\nexpiration date of December 13, 2028. The exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 and\nexpiration date of December 13, 2028. The exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":81967,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156100,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 and\nexpiration date of December 13, 2028. The exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 and\nexpiration date of December 13, 2028. The exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156099,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":81967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156098,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":81967,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156097,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":81967},"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156096,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":81967,"price":0.1844,"value":15114.7148,"ownership":{"direct":true},"balance_after":681538,"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156095,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-08T00:45:05.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":81967,"price":0.1844,"value":15114.7148,"ownership":{"direct":true},"balance_after":599571,"source":{"system":"sec-edgar","filing":"0001415889-25-012286","document":"form4-05072025_080501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588925012286/form4-05072025_080501.xml","form_type":"4"}},{"id":1156327,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant","published_at":"2025-05-07T21:48:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.5,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045741","document":"tm2514380-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465925045741/tm2514380-2_4seq1.xml","form_type":"4"}},{"id":1156326,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2025-05-07T21:48:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045741","document":"tm2514380-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465925045741/tm2514380-2_4seq1.xml","form_type":"4"}},{"id":1156325,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-05-07T21:48:30.000Z","date":"2025-05-02","kind":"purchase","planned":false,"acquired":true,"shares":1148482,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2431763,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1148482},"source":{"system":"sec-edgar","filing":"0001104659-25-045741","document":"tm2514380-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465925045741/tm2514380-2_4seq1.xml","form_type":"4"}},{"id":1156864,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant","published_at":"2025-05-07T21:47:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.5,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045738","document":"tm2514380-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925045738/tm2514380-1_4seq1.xml","form_type":"4"}},{"id":1156863,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2025-05-07T21:47:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045738","document":"tm2514380-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925045738/tm2514380-1_4seq1.xml","form_type":"4"}},{"id":1156862,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-05-07T21:47:30.000Z","date":"2025-05-02","kind":"purchase","planned":false,"acquired":true,"shares":1148482,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2431763,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1148482},"source":{"system":"sec-edgar","filing":"0001104659-25-045738","document":"tm2514380-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925045738/tm2514380-1_4seq1.xml","form_type":"4"}},{"id":1156156,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":91459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.  In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":91459,"derivative":{"exercise_price":0.45,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":91459},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156155,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156154,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.  In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.  In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156153,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":102459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.  In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.  In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":102459},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156152,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":102459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":102459},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156151,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":102459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":102459,"derivative":{"exercise_price":0.1844,"expiration_date":"2025-05-02","underlying":"Common Stock","underlying_shares":102459},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156150,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":102459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":102459},"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156149,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":11000,"price":0.1844,"value":2028.4,"ownership":{"direct":true},"balance_after":398489,"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1156148,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T20:45:07.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":102459,"price":0.1844,"value":18893.4396,"ownership":{"direct":true},"balance_after":387489,"source":{"system":"sec-edgar","filing":"0001415889-25-012287","document":"form4-05072025_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588925012287/form4-05072025_080503.xml","form_type":"4"}},{"id":1279398,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-07T21:15:16.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":343000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":343000,"derivative":{"exercise_price":0.29,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":343000},"source":{"system":"sec-edgar","filing":"0001415889-25-003346","document":"form4-02072025_040211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588925003346/form4-02072025_040211.xml","form_type":"4"}},{"id":1278301,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47898,"kind":"person","name":"Lamb Lawrence","position":1,"cik":"0001830059","reported_name":"Lamb Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CSO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-07T21:15:13.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":306750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":306750,"derivative":{"exercise_price":0.29,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":306750},"source":{"system":"sec-edgar","filing":"0001415889-25-003345","document":"form4-02072025_040208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925003345/form4-02072025_040208.xml","form_type":"4"}},{"id":1278907,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-07T21:15:10.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":338950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":338950,"derivative":{"exercise_price":0.29,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":338950},"source":{"system":"sec-edgar","filing":"0001415889-25-003344","document":"form4-02072025_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588925003344/form4-02072025_040206.xml","form_type":"4"}},{"id":1278302,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-07T21:15:07.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":912450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":912450,"derivative":{"exercise_price":0.29,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":912450},"source":{"system":"sec-edgar","filing":"0001415889-25-003343","document":"form4-02072025_040203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588925003343/form4-02072025_040203.xml","form_type":"4"}},{"id":1322540,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47897,"kind":"person","name":"Epperly Corinne","position":1,"cik":"0001839156","reported_name":"Epperly Corinne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T21:15:25.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":37655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":37655,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":37655},"source":{"system":"sec-edgar","filing":"0001415889-24-030066","document":"form4-12232024_041222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588924030066/form4-12232024_041222.xml","form_type":"4"}},{"id":1322541,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47896,"kind":"person","name":"Graff Jeremy R.","position":1,"cik":"0001975028","reported_name":"Graff Jeremy R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T21:15:23.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":47697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":47697,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":47697},"source":{"system":"sec-edgar","filing":"0001415889-24-030065","document":"form4-12232024_041220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588924030065/form4-12232024_041220.xml","form_type":"4"}},{"id":1322936,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47995,"kind":"person","name":"Greenwood Luba","position":1,"cik":"0001853815","reported_name":"Greenwood Luba","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T21:15:22.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":39449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":39449,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":39449},"source":{"system":"sec-edgar","filing":"0001415889-24-030064","document":"form4-12232024_041218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853815/000141588924030064/form4-12232024_041218.xml","form_type":"4"}},{"id":1322554,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T21:15:19.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":31559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":31559,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":31559},"source":{"system":"sec-edgar","filing":"0001415889-24-030063","document":"form4-12232024_041216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000141588924030063/form4-12232024_041216.xml","form_type":"4"}},{"id":1322539,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":51637,"kind":"person","name":"Whitfill Travis","position":1,"cik":"0001830178","reported_name":"Whitfill Travis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T21:15:18.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":42676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":42676,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":42676},"source":{"system":"sec-edgar","filing":"0001415889-24-030062","document":"form4-12232024_041215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588924030062/form4-12232024_041215.xml","form_type":"4"}},{"id":1322759,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47946,"kind":"person","name":"Brandt Peter C.","position":1,"cik":"0001434099","reported_name":"Brandt Peter C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T21:15:16.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":49490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":49490,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":49490},"source":{"system":"sec-edgar","filing":"0001415889-24-030061","document":"form4-12232024_041213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434099/000141588924030061/form4-12232024_041213.xml","form_type":"4"}},{"id":1323481,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48111,"kind":"person","name":"McCall Patrick","position":1,"cik":"0001874384","reported_name":"McCall Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-23T21:15:12.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":290085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":290085,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":290085},"source":{"system":"sec-edgar","filing":"0001415889-24-030059","document":"form4-12232024_041209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874384/000141588924030059/form4-12232024_041209.xml","form_type":"4"}},{"id":1322538,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47898,"kind":"person","name":"Lamb Lawrence","position":1,"cik":"0001830059","reported_name":"Lamb Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CSO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-23T21:15:11.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":286899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":286899,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":286899},"source":{"system":"sec-edgar","filing":"0001415889-24-030058","document":"form4-12232024_041207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588924030058/form4-12232024_041207.xml","form_type":"4"}},{"id":1323059,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-23T21:15:08.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":302839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":302839,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":302839},"source":{"system":"sec-edgar","filing":"0001415889-24-030057","document":"form4-12232024_041205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588924030057/form4-12232024_041205.xml","form_type":"4"}},{"id":1322537,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":47899,"kind":"person","name":"Ho William Tai-Wei","position":1,"cik":"0001830914","reported_name":"Ho William Tai-Wei","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-23T21:15:07.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":1188282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":1188282,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":1188282},"source":{"system":"sec-edgar","filing":"0001415889-24-030056","document":"form4-12232024_041204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740279/000141588924030056/form4-12232024_041204.xml","form_type":"4"}},{"id":1322843,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":70888,"kind":"person","name":"Roemer Alan S.","position":1,"cik":"0001643070","reported_name":"Roemer Alan S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-23T16:15:14.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":93242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date."}],"balance_after":93242,"derivative":{"exercise_price":0.24,"expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":93242},"source":{"system":"sec-edgar","filing":"0001415889-24-030060","document":"form4-12232024_041211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643070/000141588924030060/form4-12232024_041211.xml","form_type":"4"}},{"id":1387875,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387874,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.25,"exercise_date":"2023-12-13","expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387873,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":709040,"derivative":{"exercise_price":0.27,"exercise_date":"2024-10-04","expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":709040},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387872,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1283281,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387667,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1387666,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.25,"exercise_date":"2023-12-13","expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1387665,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":709040,"derivative":{"exercise_price":0.27,"exercise_date":"2024-10-04","expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":709040},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1387664,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1283281,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1389022,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2024-10-08T20:15:16.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":3038743,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 3,038,743 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share Pre-funded warrant and one Series C warrant each representing the right to purchase 3,038,743 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-funded warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-funded warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by the Malcolm and Emily Charitable Remainder Unitrust 2010 (the \"Trust\"). The Reporting Person is the trustee of the Trust."}],"balance_after":3038743,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3038743},"source":{"system":"sec-edgar","filing":"0001415889-24-024872","document":"form4-10082024_041012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000141588924024872/form4-10082024_041012.xml","form_type":"4"}},{"id":1389021,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":31448,"kind":"person","name":"FAIRBAIRN EMILY","position":1,"cik":"0001682638","reported_name":"FAIRBAIRN EMILY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Warrants (right to buy)","published_at":"2024-10-08T20:15:16.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":3038743,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 3,038,743 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share Pre-funded warrant and one Series C warrant each representing the right to purchase 3,038,743 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by the Malcolm and Emily Charitable Remainder Unitrust 2010 (the \"Trust\"). The Reporting Person is the trustee of the Trust."}],"balance_after":3038743,"derivative":{"exercise_price":0.27,"expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":3038743},"source":{"system":"sec-edgar","filing":"0001415889-24-024872","document":"form4-10082024_041012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682638/000141588924024872/form4-10082024_041012.xml","form_type":"4"}},{"id":1389440,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series C Warrants (right to buy)","published_at":"2024-10-08T20:15:13.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":25316,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":25316,"derivative":{"exercise_price":0.27,"expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":25316},"source":{"system":"sec-edgar","filing":"0001415889-24-024871","document":"form4-10082024_041010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588924024871/form4-10082024_041010.xml","form_type":"4"}},{"id":1389439,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrants (right to buy)","published_at":"2024-10-08T20:15:13.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":12295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":12295,"derivative":{"exercise_price":0.45,"expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-24-024871","document":"form4-10082024_041010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588924024871/form4-10082024_041010.xml","form_type":"4"}},{"id":1389438,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrants (right to buy)","published_at":"2024-10-08T20:15:13.000Z","date":"2024-10-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the \"old\" warrant and the grant of a \"replacement\" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.25,"expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":12295},"source":{"system":"sec-edgar","filing":"0001415889-24-024871","document":"form4-10082024_041010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588924024871/form4-10082024_041010.xml","form_type":"4"}},{"id":1389437,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":48014,"kind":"person","name":"Rochlin Kate","position":1,"cik":"0001898521","reported_name":"Rochlin Kate","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:15:13.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":25316,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock."}],"balance_after":42874,"source":{"system":"sec-edgar","filing":"0001415889-24-024871","document":"form4-10082024_041010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898521/000141588924024871/form4-10082024_041010.xml","form_type":"4"}}],"next_cursor":"2024-10-08T20:15:13.000000Z,1389437"}